Homologue-selective degraders for CDK6 have been developed and were able to significantly reduce leukemia burden in xeno-transplant experiments of Philadelphia chromosome-positive acute lymphoid leukemia with superior effects compared to CDK4/6 kinase inhibition [100]. The gene discussed is CDK6; the disease is leukemia.